Effect of phospholipid curcumin Meriva® on liver histology and kidney disease in nonalcoholic steatohepatitis a randomized, double-blind, placebo-controlled trial.

Abstract

Compared with placebo, Meriva® improved eGFR(difference in adjusted eGFR change: +3.59[2.96-4.11] mL/min/1.73 m2/year, p=0.009), fasting glucose(-17mg/dL;95%CI=-22, -12), HbA1c(-0.62%;95%CI=-0.87%, -0.37%), LDL-C(-39mg/dL; 95%CI= -45, -33), triglycerides(-36mg/dL, 95%CI= -46, -26), HDL-C(+10mg/dL; 95%CI=+8, +11) and inflammatory markers. Adverse events were rare, mild and evenly distributed. In NASH patients, Meriva® administration for 72 weeks was safe, well-tolerated, improved liver histology, possibly through NF-kB inhibition, kidney disease, and metabolic profile.